ISR Market Research

According to our CTMS Benchmarking & Market Dynamics (4th Ed.) report, 84% of survey respondents at large organizations believe it’s very important for their CTMS to have a central dashboard to track progress of multiple studies.    Our primary market research provides a look into the Clinical Trial Management Systems (CTMS) market, offering fresh insights into real user experiences with these systems and opportunities available to CTMS providers over the next few years.     We surveyed 125 experienced CTMS outsourcers and collected their insights on 303 recent engagements with service providers: https://lnkd.in/eadykvkS    This report contains a wealth of information on the provider selection process, including important criteria for choosing a CTMS provider and other factors that influence outsourcing decisions. Readers will learn which CTMS providers are perceived as leaders and how providers perform along key attributes such as Integration with EDC, IRT, eTMF and other data systems, Ease of use, Configurability / customizability for different study needs, and more.    Major Topics:  - CTMS Selection Process  - New Trends in CTMS  - CTMS Provider Perceptions  - CTMS Provider Performance  - Company Service Quality Profiles  - Appendix  - Service Provider Drill-downs  - Demographics    #clinicaldevelopment #clinicaltechnology #outsourcing #marketresearch 

In our recent Highly Potent API Manufacturing Market Outlook survey, we asked respondents, “Which therapeutic areas are drug developers’ highly potent compounds designed to target?” - The primary therapeutic area that respondents' highly potent compounds are designed to target is Oncology (74%). - Immunology (41%) follows in second position. - With roughly half as many mentions as Immunology, Neurology is the third most popular therapeutic area for highly potent compounds (22%). Gain access to the full report to uncover HPAPI insights: https://lnkd.in/edBADc_x As a drug innovator, discover how industry peers are selecting service providers and which aspects of the manufacturing process have been most challenging. As a CDMO, determine how your capabilities and marketing messaging stack up against what highly potent manufacturing outsourcers regard as important as well as the main reasons CDMOs lose the bid for an HPAPI project. #HPAPI #drugmanufacturing #biotech #pharmaceuticals #marketresearch 

Access to patient populations, Operational excellence, and Therapeutic expertise are considered to be the most important selection criteria when sponsors choose Phase I CROs. Our full Phase I CRO Benchmarking report sheds light on other critical selection attributes across three different decision-making scenarios: https://lnkd.in/e86dFFgR For this study, 169 experienced Phase I outsourcers shared their insights regarding 596 recent service provider encounters. We analyze a variety of factors around CRO selection and share performance data for 34 CROs on 21 attributes across several categories (Delivery Factors, Staff Characteristics, Accessibility, and Services). Sponsors and service providers can use this information to make the best decisions possible for their clinical development programs and service offerings. --- Sponsors: - Learn which service providers your company could utilize for your clinical development programs by identifying how each CRO has performed for your peers across a variety of metrics - Gain insight into CRO customer loyalty based on overall customer satisfaction, willingness to recommend, and likelihood to use again - Discover which attributes motivate outsourcing selection for Phase I services - Understand sponsor satisfaction with the value they received in recent Phase I engagements with each provider --- Service Providers: - Understand the selection drivers most important to sponsors when choosing Phase I service providers - Learn from recent customers how your performance compared to their expectations, across 21 attributes - Hear directly from respondents the reason(s) for their satisfaction ratings for your company’s performance - Inform your marketing messaging by understanding the areas in which respondents say you excel compared to your competitors - Understand your company’s position in the competitive landscape through brand metrics such as awareness, familiarity, and perceived leadership --- #clinicalresearch #drugdevelopment #marketresearch #pharmaceuticals Companies included in this report: Allucent / Altasciences / BioPharma Services Inc. / Biotrial / Caidya / Celerion / Centre for Human Drug Research/ CRS Clinical Research Services / CTI Clinical Trial and Consulting Services / Duke Clinical Research Institute / Eurofins / Fortrea / Frontage Laboratories, Inc / ICON plc / Innovaderm Research Inc. / IQVIA / Lambda Therapeutic Research / Medpace / Novotech / Novum Pharmaceutical Research Services / NUVISAN The Science CRO / Parexel / PPD / Precision For Medicine / Profil / ProPharma / ProSciento, Inc. / QPS Holdings, LLC / Quotient Sciences / Rho/ SGS Health Science / Spaulding Clinical Research, LLC / Syneos Health / Worldwide Clinical Trials

Pharmaceutical companies should closely monitor outsourced manufacturing trends for highly potent compounds (HPAPIs) to stay competitive, ensure product quality, and maintain regulatory compliance. As demand for targeted therapies and oncology treatments rises, many firms are leveraging specialized CDMOs that offer advanced containment technologies and expertise. Gain access to our Highly Potent API Manufacturing Market Outlook: 2024 - 2029 report on our website: https://lnkd.in/edBADc_x Staying informed about these trends helps companies access scalable production solutions, reduce infrastructure investment, and mitigate risks associated with handling potent compounds. Additionally, outsourcing to experienced partners ensures adherence to strict safety standards, accelerates time to market, and fosters innovation in drug development. This strategic awareness can ultimately enhance operational efficiency and improve patient outcomes. What you will learn: --- Drug Developers: - Gain insight into where the highly potent drug substance industry is heading over the next five years with respect to the outsourcing penetration across different manufacturing activities and types of high containment compounds - Understand the CDMO usage patterns of industry peers to identify whether additional outsourcing advantages can be obtained for your organization - Learn the criteria used by peers to help scientifically and strategically evaluate CDMOs for highly potent drug substance projects --- Contract Manufacturers: - Pinpoint which CDMO attributes have led to successful outsourcing relationships, those that have caused service providers to lose bids and what truly drives sponsor satisfaction, then internally assess your company on these metrics - Identify changes in demand for outsourced activities and services in order to prepare for future needs - Better position your company to win business by understanding the dynamics of different buyer groups and developing targeted marketing to speak directly to their unique needs --- #HPAPI #drugmanufacturing #pharmaceuticals #outsourcing

The goal of our 2024 Clinical Development Service Provider Marketing Channels Assessment report is to help clinical development service provider sales and marketing organizations understand where decision-makers go to learn about our industry and service provider offerings. ISR surveyed 150 respondents from pharmaceutical sponsor organizations after screening them to ensure they have appropriate decision-making responsibility for outsourced clinical development service provider decisions for Phase I-IV. Gain access to this report: https://lnkd.in/dN6t5Tvp If you work for a pharmaceutical sponsor organization, the data contained in this report can help you prioritize how you learn about industry trends and service providers by understanding the value your peers place on specific activities.   What you will learn: Usage and Value of Information Sources Events: - In-person industry conference/tradeshow: an in-person event with scheduled presentations/discussions as well as an exhibit hall - Virtual industry conference/tradeshow: an online, multi-part event with scheduled presentations/discussions that may or may not have a virtual exhibit hall (excluding individual webinars). - Webinar (either live or prerecorded): a one-time, 30-90-minute presentation/discussion, usually with a moderator --- Service Provider Sponsored Information: - Website information & blogs - Thought leadership - Case studies - Emails --- Sources of Industry Information: - Google - LinkedIn - News outlets - Podcasts & YouTube --- Interaction Frequency for News Outlets: - Applied Clinical Trials Magazine - BioPharma Dive - BioSpace - Citeline - Clinical Leader - Contract Pharma - DIA - Endpoints News - Fierce Biotech - Fierce Pharma - FirstWord Pharma - Outsourced Pharma - Outsourcing-Pharma - Pharmaceutical Executive - PharmaLive - Pharmalot - Pink Sheet - Scrip - STAT #clinicaldevelopment #pharmaceuticals #biotechnology #marketresearch

How will clinical development outsourcing change in the next two years? Our research into biopharma outsourcing trends and practices highlights the growing role of decentralized clinical trials, digital biomarkers, and AI in clinical trial innovation. Large sponsors ($1B+ annual R&D spend) are leading the way in adopting these advancements, with significant increases projected in the next two years. Key insights: - 65% of respondents working at large sponsor organizations expect their companies will increase the use of decentralized trials - 85% of respondents from large sponsors believe their organization will increase its focus on enrolling a demographically diverse population - 71% expect to see increased use of wearable sensors / connected health devices in clinical trials Swipe through the carousel for more data and discover how CROs are adapting to a rapidly changing landscape. #PharmaOutsourcing #CRO #ClinicalTrials #PharmaceuticalMarketResearch

What industry trends will shape your business in 2025? The pharmaceutical industry faced a variety of manufacturing complications last year, including supply chain shortages, inflation, and shipping/logistics issues: 47% of respondents with Small Molecule API outsourcing responsibilities cited supply chain shortages as a major complication in 2023. How are companies adapting? Our research reveals that many are adjusting risk mitigation strategies to ensure business continuity. Key steps include increasing contingency planning (46%) and enhancing supply chain oversight (43%). Swipe through the carousel to discover the most critical trends shaping manufacturing outsourcing today. #PharmaOutsourcing #SmallMoleculeAPI #CDMO #PharmaceuticalMarketResearch

We conducted 14 in-depth interviews with professionals who work in the External Manufacturing department at biopharmaceutical companies of various sizes (based on employee numbers and revenue) in the US and Europe. The objective of the interviews was to understand their role at their company and the part they play as an intermediary between their organization and their network of manufacturing suppliers. View more on our research portal: https://lnkd.in/eDwDFYbT This report takes an in-depth look at how members of the External Manufacturing team identify and evaluate new CDMOs, tips on how to develop strong relationships with outsourced manufacturers, how various CDMO traits and capabilities influence their selection decision, and general preferences these interviewees have developed over their careers. Additionally, ISR asked about the main challenges External Manufacturing professionals are currently facing as well as potential solutions to these challenges. What you will learn: --- Drug Developers: - How experienced outsourcers identify new CDMOs - Potential solutions to outsourcing and supply chain challenges - Key components to establishing successful relationships with contract manufacturers --- Contract Manufacturers: - Which CDMO traits matter the most when choosing a new CDMO - How cost, equipment, and geography factor into CDMO selection - What outsourcers look for during their due diligence site visit --- Major Topics: - External Manufacturing’s Role in the CDMO Selection Process - The CDMO Evaluation Process - Factors that Influence CDMO Selection - Vendor Preferences - Main Outsourcing Challenges and Potential Solutions #drugmanufacturing #outsourcing #pharmaceuticals #marketresearch

ISR’s primary market research provides a look into the Clinical Trial Management Systems (CTMS) market, offering fresh insights into real user experiences with these systems and opportunities available to CTMS providers over the next few years. Our CTMS Benchmarking & Market Dynamics (4th Ed.) report contains a wealth of information on the provider selection process, including important criteria for choosing a CTMS provider and other factors that influence outsourcing decisions. Gain access to this report on our website: https://lnkd.in/eadykvkS Respondents evaluated recently used CTMS providers on their performance across 18 key attributes and shared verbatim feedback for their preferred CTMS providers. This research also offers a pulse on new trends, including improvements to centralized monitoring capabilities within CTMS, possible AI applications, and the importance of professional services offered by CTMS providers.   What you will learn: --- Sponsors and CROs: - Discover which attributes motivate outsourcing selection for CTMS services - Learn which CTMS providers are considered leaders and being most utilized by your peers - Understand how CTMS providers are performing along a variety of attributes and which might be a good fit for your studies --- CTMS Providers: - Understand how sponsors and CROs choose CTMS providers including selection attributes, use of preferred providers, contracting / bundling preferences, etc. - Utilize the experience of recent customers to benchmark CTMS provider performance across 18 attributes and gauge the performance of your company against users’ expectations as well as that of competitors - Read verbatim responses to understand why respondents prefer specific solutions and what improvements they would like to see in future versions of CTMS - Learn about recent trends in the CTMS space including AI applications, centralized monitoring capabilities, and feature usage   --- Providers included in this report: LifeSphere by ArisGlobal / Axiom Real-Time Metrics / BSI Life Sciences / Clinevo Technologies / Cloudbyz CTMS / Ennov / Fortrea (formerly Labcorp / Covance) / Fountayn / IQVIA / Medidata Solutions / Medpace / Octalsoft (Glorant LLC) / Oracle / PPD / Premier Research / SimpleTrials CTMS & eTMF / Sitero (Formerly Clario / Bioclinica / ERT) / TransPerfect / Veeva Systems --- Major Topics: - CTMS Selection Process - New Trends in CTMS - CTMS Provider Perceptions - CTMS Provider Performance - Company Service Quality Profiles - Appendix - Service Provider Drill-downs - Demographics #clinicaldevelopment #clinicaltechnology #outsourcing #marketresearch

Operational excellence and Therapeutic expertise are considered very important when sponsors select Phase II/III CROs. Our Phase II/III CRO Benchmarking report sheds light on other critical selection attributes across three decision-making scenarios. For this study, 232 experienced Phase II/III outsourcers shared their insights regarding 824 recent service provider encounters. We analyze a variety of factors around CRO selection and share performance data for 31 CROs on 21 attributes across several categories (Delivery Factors, Staff Characteristics, Services, and Project Delivery across geographies). Sponsors and service providers can use this information to make the best decisions possible for their clinical development programs and service offerings. View more on our research portal: https://lnkd.in/eGrycUFh What you will learn: --- Sponsors: - Gain insight into CRO customer loyalty based on overall customer satisfaction, willingness to recommend, and likelihood to use again - Learn which service providers your company could utilize for your clinical development programs by identifying how each CRO has performed for your peers across a variety of metrics - Discover which attributes motivate outsourcing selection for Phase II/III services - Understand sponsor satisfaction with the value they received in recent Phase II/III engagements with each provider --- Service Providers: - Understand the selection drivers most important to sponsors when choosing Phase II/III service providers - Learn from recent customers how your performance compared to their expectations, across 21 attributes - Hear directly from respondents the reason(s) for their satisfaction ratings for your company’s performance - Inform your marketing messaging by understanding the areas in which respondents say you excel compared to your competitors - Understand where your company and your competitors fall on brand metrics such as awareness, familiarity, and perceived leadership --- Companies included in this report: Advanced Clinical / Allucent / Altasciences /Caidya / ClinChoice / Duke Clinical Research Institute / Eurofins / Fortrea / Frontage Laboratories, Inc / George Clinical / ICON plc / Innovaderm Research Inc. / inSeption Group / IQVIA / Lambda Therapeutic Research / Medpace / Novotech / Novum Pharmaceutical Research Services / Ora / Parexel / PPD / Precision For Medicine / Premier Research / ProPharma / PSI CRO AG / QPS Holdings, LLC / Rho / SGS / Syneos Health / UBC / Worldwide Clinical Trials #clinicaltrials #outsourcing #pharmaceuticals #marketresearch